As preclinical studies also suggest that the AHR is responsible for mediating – at least in part – the immunosuppressive effects of cancer-derived TRP metabolites (34, 48), the AHR represents a logical pharmaceutical target for cancer immunotherapy. Here, AHR is linked to cancer.